PTAB shoots down tenth I-MAK Gilead challenge

The Patent Trial and Appeal Board (PTAB) has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB rejects IPR challenges to Gilead patents

14 June 2018 The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

Asia

AbbVie faces hepatitis C patent challenge in India

26 July 2018 In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.

Americas

Patent abuse driving high drug prices, non-profit claims

2 August 2018 Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge.

More on this story

Americas

PTAB rejects IPR challenges to Gilead patents

14 June 2018 The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

Asia

AbbVie faces hepatitis C patent challenge in India

Americas

Patent abuse driving high drug prices, non-profit claims

More on this story

Americas

PTAB rejects IPR challenges to Gilead patents

14 June 2018 The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

Asia

AbbVie faces hepatitis C patent challenge in India

Americas

Patent abuse driving high drug prices, non-profit claims